Royal Fund Management, LLC Abb Vie Inc. Transaction History

Royal Fund Management, LLC

$984 Million
Q1 2024

A detailed history of Royal Fund Management, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Royal Fund Management, LLC holds 47,303 shares of ABBV stock, worth $8.11 Million. This represents 0.87% of its overall portfolio holdings.

Number of Shares

47,303

Previous 2,900 1531.14%

Holding current value

$8.11 Million

Previous $449,000 1818.26%

% of portfolio

0.87%

Previous 0.05%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 11, 2024	SELL	$159.82 - $182.1 $96,371 - $109,806	-603 Reduced 1.26%	47,303 $8.61 Million
Q4 2023 Feb 06, 2024	SELL	$137.6 - $154.97 $27,382 - $30,839	-199 Reduced 0.41%	47,906 $7.42 Million
Q3 2023 Oct 17, 2023	SELL	$133.59 - $154.65 $177,140 - $205,065	-1,326 Reduced 2.68%	48,105 $7.17 Million
Q2 2023 Jul 12, 2023	BUY	$132.51 - $164.9 $530,702 - $660,424	4,005 Added 8.82%	49,431 $6.66 Million
Q1 2023 Apr 10, 2023	BUY	$144.61 - $166.54 $429,057 - $494,124	2,967 Added 6.99%	45,426 $7.24 Million

Q4 2022 Jan 20, 2023	BUY	$138.31 - $165.87 $460,157 - $551,849	3,327 Added 8.5%	42,459 $0
Q3 2022 Nov 14, 2022	SELL	$134.21 - $153.93 $278,351 - $319,250	-2,074 Reduced 5.03%	39,132 $5.25 Million
Q2 2022 Jul 28, 2022	BUY	$137.62 - $174.96 $260,652 - $331,374	1,894 Added 4.82%	41,206 $6.31 Million
Q1 2022 May 13, 2022	SELL	$131.98 - $163.75 $129,472 - $160,638	-981 Reduced 2.43%	39,312 $6.37 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $53,392 - $67,557	497 Added 1.25%	40,293 $5.46 Million
Q3 2021 Oct 20, 2021	BUY	$106.4 - $120.78 $77,459 - $87,927	728 Added 1.86%	39,796 $4.29 Million
Q2 2021 Jul 26, 2021	SELL	$105.21 - $117.21 $88,271 - $98,339	-839 Reduced 2.1%	39,068 $4.4 Million
Q1 2021 Apr 29, 2021	BUY	$102.3 - $112.62 $166,646 - $183,457	1,629 Added 4.26%	39,907 $4.32 Million
Q4 2020 Feb 02, 2021	SELL	$80.49 - $108.67 $193,739 - $261,568	-2,407 Reduced 5.92%	38,278 $4.1 Million
Q3 2020 Oct 13, 2020	SELL	$85.91 - $100.83 $387,969 - $455,348	-4,516 Reduced 9.99%	40,685 $3.56 Million
Q2 2020 Aug 06, 2020	BUY	$73.37 - $98.18 $645,289 - $863,493	8,795 Added 24.16%	45,201 $4.44 Million
Q1 2020 May 08, 2020	SELL	$64.5 - $97.79 $3.7 Million - $5.6 Million	-57,288 Reduced 61.14%	36,406 $2.77 Million
Q4 2019 May 11, 2020	SELL	$72.13 - $90.25 $726,998 - $909,629	-10,079 Reduced 9.71%	93,694 $8.3 Million
Q3 2019 May 08, 2020	BUY	$62.98 - $75.72 $1.81 Million - $2.18 Million	28,789 Added 38.39%	103,773 $7.86 Million
Q2 2019 May 08, 2020	SELL	$65.7 - $83.98 $365,423 - $467,096	-5,562 Reduced 6.91%	74,984 $5.45 Million
Q1 2019 May 11, 2020	SELL	$77.14 - $90.79 $131,292 - $154,524	-1,702 Reduced 2.07%	80,546 $6.49 Million
Q4 2018 May 07, 2020	SELL	$77.85 - $96.01 $5.24 Million - $6.46 Million	-67,291 Reduced 45.0%	82,248 $7.58 Million
Q3 2018 May 07, 2020	SELL	$88.91 - $98.84 $318,208 - $353,748	-3,579 Reduced 2.34%	149,539 $14.1 Million
Q2 2018 May 07, 2020	BUY	$89.78 - $106.23 $1.54 Million - $1.82 Million	17,160 Added 12.62%	153,118 $14.2 Million
Q1 2018 May 07, 2020	SELL	$92.01 - $123.21 $2.1 Million - $2.82 Million	-22,870 Reduced 14.4%	135,958 $12.9 Million
Q4 2017 May 07, 2020	SELL	$89.56 - $98.21 $390,660 - $428,392	-4,362 Reduced 2.67%	158,828 $15.4 Million
Q3 2017 May 07, 2020	SELL	$69.85 - $89.22 $256,908 - $328,151	-3,678 Reduced 2.2%	163,190 $14.5 Million
Q2 2017 May 07, 2020	BUY	N/A	6,198 Added 3.86%	166,868 $12.1 Million
Q1 2017 May 07, 2020	BUY	N/A	19,286 Added 13.64%	160,670 $10.5 Million
Q4 2016 May 07, 2020	BUY	N/A	141,384	141,384 $8.85 Million

Others Institutions Holding ABBV

# of Institutions

3,651

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Royal Fund Management, LLC with notifications on news.

Account

Royal Fund Management, LLC Abb Vie Inc. Transaction History